Your session is about to expire
← Back to Search
DVX201 for Acute Myeloid Leukemia
Study Summary
This trial is testing an investigational cell therapy, DVX201, to see if it can help patients with leukemia or myelodysplastic syndrome.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this investigation still taking on participants?
"Affirmative. Clinicaltrials.gov states that this research trial, which commenced on December 15th 2021, is actively searching for participants to fill the 18 slots available at 1 medical facility."
How many participants can take part in this research study?
"Affirmative, clinicaltrials.gov provides evidence that this trial is still recruiting participants. It was initially posted on December 15th 2021 and has been revised most recently as of February 11th 2022. The study requires 18 test subjects across 1 site to complete their research project."
Has the FDA granted authorization to DVX201?
"As DVX201 is in its initial phase of clinical trials, our team at Power has only allocated a score of 1 to the drug's safety profile due to limited evidence supporting efficacy and safety."
Share this study with friends
Copy Link
Messenger